TABLE 2.

Comparison of the HI results of various experiments of vaccination with CPV-2 reported in the literature and the results of this study

HI titer	Strain and vaccine information or no. of pups with an active response/no. of pups vaccinated (%)a
	Pratelli et al. (32)b: CPV-2b strain 29/97, 40th passage; parenteral; titer, 4.5 TCID50	This paperb; CPV-2b strain 29/97, 68th passage; intranasal; titer, 4.5 TCID50	Buonavoglia et al. (3)b; CPV-2 strain 17-80, ISS, >60th passage; parenteral; titer, 7.0 TCID50	Buonavoglia et al. (2)b; CPV-2 strain 17-80, ISS, >60th passage; intranasal; titer 5.5 TCID50	Carmichael et al (11); CPV-2 strain A, 100-115th passage; parenteral; titer, 5.5 TCID50	Burtonboy et al. (8); CPV-2 strain NL-35-D, 37th passage; parenteral; titer, 7.0 TCID50	Hoare et al. (17); CPV-2 strain NL-35-D, 13th passage; parenteral; titer, 7.0 TCID50
<8						1/1 (100)	28/29 (96.5)
8						19/20 (95)	16/17 (94.1)
10	1/1 (100)	2/2 (100)	NTc	NT	(98)
16						24/27 (89)	45/45 (100)
20	4/4 (100)	8/8 (100)	NT	NT	(50)
32						18/22 (82)	31/33 (93.9)
40	12/12 (100)	20/20 (100)	72/78 (92.3)	14/14 (100)
64						2/5 (40)	13/13 (100)
80	10/12 (83)	13/13 (100)		8/11 (72.7)	(0)
128						2/3 (66)	2/3 (66)
160	4/7 (57)	10/15 (66.6)	0/128 (0)	3/17 (17.6)
256						0/1 (0)	6/6 (100)
320	3/5 (60)	6/16 (37.5)		0/6 (0)
640	NT	0/4 (0)		0/11 (0)

^aDifferences in laboratory standardization may slightly affect the results reported in the various experiments.

^bThe results reported for these studies were obtained in the same laboratory.

^cNT, not tested.